Stuart J Connolly, MD
November 4th, 2013
Should Plasma Levels of Dabigatran Guide How We Dose the Drug?
Stuart J Connolly, MD
Stuart J. Connolly discusses his research group’s analysis of data from the RE-LY trial, concerning the relationship between plasma concentrations of dabigatran and the risks for ischemic events and major bleeding.
NEJM Journal Watch — Recent Cardiology Articles- Sex-Based Disparity in CABG Outcomes: Are We Moving Toward Parity?
- Can Genetic and Social Risk Scores Improve Cardiac Risk Prediction?
- Extensive Ablation vs. Pulmonary Vein Isolation in Persistent Atrial Fibrillation
- Can a Novel Stent Design Improve Long-Term Outcomes of Percutaneous Coronary Intervention?
- Are Angiographically-Derived Coronary Physiology Measurements Ready for Use in the Cath Lab?